<H1>Chapter DOI: 10.1007/978-1-60327-829-4_17<br/>Cited-By Count: 1</H1><table border="1" width="30%"><tr><td>Total References</td><td>84</td></tr><tr><td>Springer references</td><td>2</td></tr><tr><td>Non Springer references</td><td>82</td></tr><tr><td>BibStructured Count</td><td width="10%">84</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>66</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>2</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>2</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>2</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_17</td><td>BibArticle</td><td>Ide AG, Baker NH, Warren SL. Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamger. Am J Roentgenol 1939;42:891&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR2_17</td><td>BibArticle</td><td>Algire GH, Chalkley HW, Legallais FY, Park HD. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 1945;6:73&#8211;85.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR3_17</td><td>BibArticle</td><td>Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971;133:275&#8211;88.</td><td><a href=http://dx.doi.org/10.1084/jem.133.2.275>10.1084/jem.133.2.275</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4_17</td><td>BibArticle</td><td>Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182&#8211;6.</td><td><a href=http://dx.doi.org/10.1056/NEJM197108122850711>10.1056/NEJM197108122850711</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5_17</td><td>BibArticle</td><td>Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002;282:C947&#8211;70.</td><td><a href=http://dx.doi.org/10.1152/ajpcell.00389.2001>10.1152/ajpcell.00389.2001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6_17</td><td>BibArticle</td><td>Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353&#8211;64.</td><td><a href=http://dx.doi.org/10.1016/S0092-8674(00)80108-7>10.1016/S0092-8674(00)80108-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7_17</td><td>BibArticle</td><td>Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 1993;328:1237&#8211;43.</td><td><a href=http://dx.doi.org/10.1056/NEJM199304293281706>10.1056/NEJM199304293281706</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8_17</td><td>BibArticle</td><td>Folkman J, Kalluri R. Cancer without disease. Nature 2004;427:787.</td><td><a href=http://dx.doi.org/10.1038/427787a>10.1038/427787a</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_17</td><td>BibArticle</td><td>Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis &#8211; correlation in invasive breast carcinoma. N Engl J Med 1991;324:1&#8211;8.</td><td><a href=http://dx.doi.org/10.1056/NEJM199101033240101>10.1056/NEJM199101033240101</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10_17</td><td>BibArticle</td><td>Udagawa T, Fernandez A, Achilles EG, Folkman J, D&#8217;Amato RJ. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J 2002;16:1361&#8211;70.</td><td><a href=http://dx.doi.org/10.1096/fj.01-0813com>10.1096/fj.01-0813com</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11_17</td><td>BibArticle</td><td>Naumov GN, Bender E, Zurakowski D, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006;98:316&#8211;25.</td><td><a href=http://dx.doi.org/10.1093/jnci/djj068>10.1093/jnci/djj068</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12_17</td><td>BibArticle</td><td>Holmgren L, O&#8217;Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149&#8211;53.</td><td><a href=http://dx.doi.org/10.1038/nm0295-149>10.1038/nm0295-149</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13_17</td><td>BibArticle</td><td>Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994&#8211;8.</td><td><a href=http://dx.doi.org/10.1126/science.284.5422.1994>10.1126/science.284.5422.1994</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14_17</td><td>BibArticle</td><td>Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR15_17</td><td>BibArticle</td><td>Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669&#8211;76.</td><td><a href=http://dx.doi.org/10.1038/nm0603-669>10.1038/nm0603-669</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16_17</td><td>BibArticle</td><td>Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997;277:242&#8211;5.</td><td><a href=http://dx.doi.org/10.1126/science.277.5323.242>10.1126/science.277.5323.242</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17_17</td><td>BibArticle</td><td>Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6:507&#8211;16.</td><td><a href=http://dx.doi.org/10.1016/j.ccr.2004.09.030>10.1016/j.ccr.2004.09.030</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18_17</td><td>BibArticle</td><td>Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998;394:485&#8211;90.</td><td><a href=http://dx.doi.org/10.1038/28867>10.1038/28867</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19_17</td><td>BibArticle</td><td>Folkman J. Endogenous angiogenesis inhibitors. APMIS 2004;112:496&#8211;507.</td><td><a href=http://dx.doi.org/10.1111/j.1600-0463.2004.apm11207-0809.x>10.1111/j.1600-0463.2004.apm11207-0809.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20_17</td><td>BibArticle</td><td>Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005;65:3967&#8211;79.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-04-2427>10.1158/0008-5472.CAN-04-2427</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21_17</td><td>BibArticle</td><td>Rak J, Yu JL, Klement G, Kerbel RS. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Investig Dermatol Symp Proc 2000;5:24&#8211;33.</td><td><a href=http://dx.doi.org/10.1046/j.1087-0024.2000.00012.x>10.1046/j.1087-0024.2000.00012.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22_17</td><td>BibArticle</td><td>Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science 1980;208:516&#8211;8.</td><td><a href=http://dx.doi.org/10.1126/science.6154315>10.1126/science.6154315</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23_17</td><td>BibArticle</td><td>Dvorak HF, Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 1989;81:497&#8211;502.</td><td><a href=http://dx.doi.org/10.1093/jnci/81.7.497>10.1093/jnci/81.7.497</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24_17</td><td>BibArticle</td><td>Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987;47:5155&#8211;61.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR25_17</td><td>BibArticle</td><td>Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis. Nature 1982;297:307&#8211;12.</td><td><a href=http://dx.doi.org/10.1038/297307a0>10.1038/297307a0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26_17</td><td>BibArticle</td><td>Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985;230:1375&#8211;8.</td><td><a href=http://dx.doi.org/10.1126/science.2416056>10.1126/science.2416056</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27_17</td><td>BibArticle</td><td>Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990;348:555&#8211;7.</td><td><a href=http://dx.doi.org/10.1038/348555a0>10.1038/348555a0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28_17</td><td>BibArticle</td><td>O&#8217;Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315&#8211;28.</td><td><a href=http://dx.doi.org/10.1016/0092-8674(94)90200-3>10.1016/0092-8674(94)90200-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29_17</td><td>BibArticle</td><td>O&#8217;Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277&#8211;85.</td><td><a href=http://dx.doi.org/10.1016/S0092-8674(00)81848-6>10.1016/S0092-8674(00)81848-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30_17</td><td>BibArticle</td><td>Folkman J. Antiangiogenesis in cancer therapy &#8211; endostatin and its mechanisms of action. Exp Cell Res 2006;312:594&#8211;607.</td><td><a href=http://dx.doi.org/10.1016/j.yexcr.2005.11.015>10.1016/j.yexcr.2005.11.015</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31_17</td><td>BibArticle</td><td>Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002;6:1&#8211;12.</td><td><a href=http://dx.doi.org/10.1111/j.1582-4934.2002.tb00307.x>10.1111/j.1582-4934.2002.tb00307.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32_17</td><td>BibArticle</td><td>Maeshima Y, Manfredi M, Reimer C, et al. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem 2001;276:15240&#8211;8.</td><td><a href=http://dx.doi.org/10.1074/jbc.M007764200>10.1074/jbc.M007764200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33_17</td><td>BibArticle</td><td>Sund M, Hamano Y, Sugimoto H, et al. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci U S A 2005;102:2934&#8211;9.</td><td><a href=http://dx.doi.org/10.1073/pnas.0500180102>10.1073/pnas.0500180102</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34_17</td><td>BibArticle</td><td>Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582&#8211;4.</td><td><a href=http://dx.doi.org/10.1126/science.7521539>10.1126/science.7521539</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35_17</td><td>BibArticle</td><td>Zhang L, Yu D, Hu M, et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 2000;60:3655&#8211;61.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR36_17</td><td>BibArticle</td><td>Sherif ZA, Nakai S, Pirollo KF, Rait A, Chang EH. Downmodulation of bFGF-binding protein expression following restoration of p53 function. Cancer Gene Ther 2001;8:771&#8211;82.</td><td><a href=http://dx.doi.org/10.1038/sj.cgt.7700361>10.1038/sj.cgt.7700361</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37_17</td><td>BibArticle</td><td>Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000;14:34&#8211;44.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR38_17</td><td>BibArticle</td><td>Teodoro JG, Parker AE, Zhu X, Green MR. p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 2006;313:968&#8211;71.</td><td><a href=http://dx.doi.org/10.1126/science.1126391>10.1126/science.1126391</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39_17</td><td>BibArticle</td><td>Folkman J. Tumor suppression by p53 is mediated in part by the antiangiogenic activity of endostatin and tumstatin. Sci STKE 2006;2006:pe35.</td><td><a href=http://dx.doi.org/10.1126/stke.3542006pe35>10.1126/stke.3542006pe35</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40_17</td><td>BibArticle</td><td>Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, Novario R. Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 2002;5:123&#8211;7.</td><td><a href=http://dx.doi.org/10.1038/sj.pcan.4500572>10.1038/sj.pcan.4500572</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41_17</td><td>BibArticle</td><td>Borre M, Offersen BV, Nerstrom B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998;78:940&#8211;4.</td><td><a href=http://dx.doi.org/10.1038/bjc.1998.605>10.1038/bjc.1998.605</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42_17</td><td>BibArticle</td><td>Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR43_17</td><td>BibArticle</td><td>Borre M, Nerstrom B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 2000;6:1882&#8211;90.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR44_17</td><td>BibArticle</td><td>Kuniyasu H, Troncoso P, Johnston D, et al. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 2000;6:2295&#8211;308.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR45_17</td><td>BibArticle</td><td>Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999;54:523&#8211;7.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(99)00167-3>10.1016/S0090-4295(99)00167-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR46_17</td><td>BibArticle</td><td>Meyer GE, Yu E, Siegal JA, Petteway JC, Blumenstein BA, Brawer MK. Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer 1995;76:2304&#8211;11.</td><td><a href=http://dx.doi.org/10.1002/1097-0142(19951201)76:11&lt;2304::AID-CNCR2820761119&gt;3.0.CO;2-N>10.1002/1097-0142(19951201)76:11&lt;2304::AID-CNCR2820761119&gt;3.0.CO;2-N</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR47_17</td><td>BibArticle</td><td>Trojan L, Thomas D, Knoll T, Grobholz R, Alken P, Michel MS. Expression of pro-angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularisation in prostate cancer. Urol Res 2004;32:97&#8211;103.</td><td><a href=http://dx.doi.org/10.1007/s00240-003-0383-5>10.1007/s00240-003-0383-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR48_17</td><td>BibArticle</td><td>West AF, O&#8217;Donnell M, Charlton RG, Neal DE, Leung HY. Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. Br J Cancer 2001;85:576&#8211;83.</td><td><a href=http://dx.doi.org/10.1054/bjoc.2001.1971>10.1054/bjoc.2001.1971</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR49_17</td><td>BibArticle</td><td>Lehrer S, Diamond EJ, Mamkine B, Stone NN, Stock RG. Serum interleukin-8 is elevated in men with prostate cancer and bone metastases. Technol Cancer Res Treat 2004;3:411.</td><td><a href=http://dx.doi.org/10.1177/153303460400300501>10.1177/153303460400300501</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_1, VolumeID, Year, ArticleTitle, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR50_17</td><td>BibArticle</td><td>Murphy C, McGurk M, Pettigrew J, et al. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res 2005;11:4117&#8211;27.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-04-1518>10.1158/1078-0432.CCR-04-1518</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR51_17</td><td>BibArticle</td><td>Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 2002;51:268&#8211;75.</td><td><a href=http://dx.doi.org/10.1002/pros.10083>10.1002/pros.10083</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR52_17</td><td>BibArticle</td><td>Mehta R, Kyshtoobayeva A, Kurosaki T, et al. Independent association of angiogenesis index with outcome in prostate cancer. Clin Cancer Res 2001;7:81&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR53_17</td><td>BibArticle</td><td>Strohmeyer D, Rossing C, Bauerfeind A, et al. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 2000;45:216&#8211;24.</td><td><a href=http://dx.doi.org/10.1002/1097-0045(20001101)45:3&lt;216::AID-PROS3&gt;3.0.CO;2-C>10.1002/1097-0045(20001101)45:3&lt;216::AID-PROS3&gt;3.0.CO;2-C</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR54_17</td><td>BibArticle</td><td>Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol 2000;17:445&#8211;51.</td><td><a href=http://dx.doi.org/10.3892/ijo.17.3.445>10.3892/ijo.17.3.445</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_2, Author_FamilyName_1, JournalTitle, Year</td><td>CrossRef</td></tr><tr><td>CR55_17</td><td>BibArticle</td><td>Sivridis E, Giatromanolaki A, Papadopoulos I, Gatter KC, Harris AL, Koukourakis MI. Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis. Br J Cancer 2002;86:1465&#8211;71.</td><td><a href=http://dx.doi.org/10.1038/sj.bjc.6600281>10.1038/sj.bjc.6600281</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR56_17</td><td>BibArticle</td><td>Abdulkadir SA, Carvalhal GF, Kaleem Z, et al. Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 2000;31:443&#8211;7.</td><td><a href=http://dx.doi.org/10.1053/hp.2000.6547>10.1053/hp.2000.6547</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR57_17</td><td>BibArticle</td><td>Du Z, Fujiyama C, Chen Y, Masaki Z. Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue. Chin Med J (Engl) 2003;116:1936&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR58_17</td><td>BibArticle</td><td>Zhong H, Semenza GL, Simons JW, De Marzo AM. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev 2004;28:88&#8211;93.</td><td><a href=http://dx.doi.org/10.1016/j.cdp.2003.12.009>10.1016/j.cdp.2003.12.009</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR59_17</td><td>BibArticle</td><td>Mazzucchelli R, Montironi R, Santinelli A, Lucarini G, Pugnaloni A, Biagini G. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 2000;45:72&#8211;9.</td><td><a href=http://dx.doi.org/10.1002/1097-0045(20000915)45:1&lt;72::AID-PROS9&gt;3.0.CO;2-U>10.1002/1097-0045(20000915)45:1&lt;72::AID-PROS9&gt;3.0.CO;2-U</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR60_17</td><td>BibArticle</td><td>Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005;41:858&#8211;7.</td><td><a href=http://dx.doi.org/10.1016/j.ejca.2004.12.035>10.1016/j.ejca.2004.12.035</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR61_17</td><td>BibArticle</td><td>Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3&#8242;-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 2003;9:2416&#8211;25.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR62_17</td><td>BibArticle</td><td>Horii K, Suzuki Y, Kondo Y, et al. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells. Mol Cancer Res 2007;5:383&#8211;91.</td><td><a href=http://dx.doi.org/10.1158/1541-7786.MCR-06-0226>10.1158/1541-7786.MCR-06-0226</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR63_17</td><td>BibArticle</td><td>Fu XS, Choi E, Bubley GJ, Balk SP. Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate 2005;63:215&#8211;21.</td><td><a href=http://dx.doi.org/10.1002/pros.20190>10.1002/pros.20190</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR64_17</td><td>BibArticle</td><td>Chau CH, Permenter MG, Steinberg SM, et al. Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer. Cancer Biol Ther 2005;4:1222&#8211;5.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR65_17</td><td>BibArticle</td><td>Orr-Urtreger A, Bar-Shira A, Matzkin H, Mabjeesh NJ. The homozygous P582S mutation in the oxygen-dependent degradation domain of HIF-1 alpha is associated with increased risk for prostate cancer. Prostate 2007;67:8&#8211;13.</td><td><a href=http://dx.doi.org/10.1002/pros.20433>10.1002/pros.20433</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR66_17</td><td>BibArticle</td><td>Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991;13:31&#8211;6.</td><td><a href=http://dx.doi.org/10.1002/bies.950130106>10.1002/bies.950130106</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR67_17</td><td>BibArticle</td><td>Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273&#8211;86.</td><td><a href=http://dx.doi.org/10.1038/nrd2115>10.1038/nrd2115</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR68_17</td><td>BibArticle</td><td>Nikolopoulos SN, Blaikie P, Yoshioka T, Guo W, Giancotti FG. Integrin beta4 signaling promotes tumor angiogenesis. Cancer Cell 2004;6:471&#8211;83.</td><td><a href=http://dx.doi.org/10.1016/j.ccr.2004.09.029>10.1016/j.ccr.2004.09.029</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR69_17</td><td>BibArticle</td><td>Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006;312:1171&#8211;5.</td><td><a href=http://dx.doi.org/10.1126/science.1125950>10.1126/science.1125950</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR70_17</td><td>BibArticle</td><td>Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58&#8211;62.</td><td><a href=http://dx.doi.org/10.1126/science.1104819>10.1126/science.1104819</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR71_17</td><td>BibArticle</td><td>Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878&#8211;86.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR72_17</td><td>BibArticle</td><td>Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15&#8211;24.</td><td><a href=http://dx.doi.org/10.1172/JCI8829>10.1172/JCI8829</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR73_17</td><td>BibArticle</td><td>Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003;63:4342&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR74_17</td><td>BibArticle</td><td>Mancuso P, Colleoni M, Calleri A, et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006;108:452&#8211;9.</td><td><a href=http://dx.doi.org/10.1182/blood-2005-11-4570>10.1182/blood-2005-11-4570</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR75_17</td><td>BibArticle</td><td>Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423&#8211;36.</td><td><a href=http://dx.doi.org/10.1038/nrc1369>10.1038/nrc1369</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR76_17</td><td>BibArticle</td><td>Hudis CA. Clinical implications of antiangiogenic therapies. Oncology (Williston Park) 2005;19:26&#8211;31.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR77_17</td><td>BibArticle</td><td>Davis DW, McConkey DJ, Abbruzzese JL, Herbst RS. Surrogate markers in antiangiogenesis clinical trials. Br J Cancer 2003;89:8&#8211;14.</td><td><a href=http://dx.doi.org/10.1038/sj.bjc.6601035>10.1038/sj.bjc.6601035</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR78_17</td><td>BibArticle</td><td>Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002;295:1526&#8211;8.</td><td><a href=http://dx.doi.org/10.1126/science.1068327>10.1126/science.1068327</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR79_17</td><td>BibArticle</td><td>Glade Bender J, Cooney EM, Kandel JJ, Yamashiro DJ. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Updat 2004;7:289&#8211;300.</td><td><a href=http://dx.doi.org/10.1016/j.drup.2004.09.001>10.1016/j.drup.2004.09.001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR80_17</td><td>BibArticle</td><td>Sweeney CJ, Miller KD, Sledge GW, Jr. Resistance in the anti-angiogenic era: nay-saying or a word of caution? Trends Mol Med 2003;9:24&#8211;9.</td><td><a href=http://dx.doi.org/10.1016/S1471-4914(02)00007-2>10.1016/S1471-4914(02)00007-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR81_17</td><td>BibArticle</td><td>Kerbel RS, Yu J, Tran J, et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001;20:79&#8211;86.</td><td><a href=http://dx.doi.org/10.1023/A:1013172910858>10.1023/A:1013172910858</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR82_17</td><td>BibArticle</td><td>Streubel B, Chott A, Huber D, et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004;351:250&#8211;9.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa033153>10.1056/NEJMoa033153</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR83_17</td><td>BibArticle</td><td>Hida K, Hida Y, Amin DN, et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004;64:8249&#8211;55.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-04-1567>10.1158/0008-5472.CAN-04-1567</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR84_17</td><td>BibArticle</td><td>Walsh K, Sherwood RA, Dew TK, Mulvin D. Angiogenic peptides in prostatic disease. BJU Int 1999;84:1081&#8211;3.</td><td><a href=http://dx.doi.org/10.1046/j.1464-410x.1999.00363.x>10.1046/j.1464-410x.1999.00363.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>